Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation

Nuravax announced on October 20, 2026, that FDA granted fast track designation to AV-1959R, the company's lead investigational amyloid-beta (Aβ) vaccine, for the prevention of Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid pathology.¹ No preventive therapy is currently approved for this population.¹

Nuravax, an Irvine, California–based spin-out of the nonprofit Institute for Molecular Medicine (IMM), plans to evaluate the vaccine in AREVIA, a phase 2 prevention study in amyloid-positive, cognitively unimpaired adults.¹

"Alzheimer's therapeutics are shifting from slowing disease in people with symptoms toward stopping it before it starts," said Michael G. Agadjanyan, PhD, president of Nuravax and head of molecular immunology at IMM, in a company press release.¹ "Our goal is to stop amyloid buildup in people who are at risk but have no symptoms, and ultimately to delay or even prevent dementia."

What does fast track designation provide?

FDA's fast track process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.² Lon S. Schneider, MD, professor of psychiatry, neurology, and gerontology at the Keck School of Medicine of the University of Southern California and a medical consultant to Nuravax, said in the release the designation "enables more frequent interaction with the FDA, which could help streamline development." He added that it also supports early dialogue on phase 3 design, eligibility for rolling review, and, if criteria are met, accelerated approval and priority review.¹

What did the phase 1 study show?

According to Dr Agadjanyan, the designation request was supported by published preclinical results and phase 1 data demonstrating the vaccine's safety and immunogenicity.¹ The randomized, placebo-controlled, double-blind phase 1 trial, published in Molecular Neurodegeneration, enrolled 16 cognitively unimpaired participants. In the trial, 12 participants received AV-1959R at 100 µg or 300 µg, and 4 received placebo.³ All 12 vaccine recipients developed anti-Aβ antibody responses after 2 doses given 1 month apart, with geometric mean titers of 60,240 in the 100-µg cohort and 69,530 in the 300-µg cohort; no placebo recipient showed a measurable response.³

How will the AREVIA phase 2 study be designed?

AREVIA (NCT07827768)⁴ is expected to enroll 160 cognitively unimpaired adults with biomarker-confirmed amyloid pathology.¹ Participants will receive 2 priming immunizations of AV-1959R followed by a booster at week 44. The study will assess safety, including magnetic resonance imaging monitoring for amyloid-related imaging abnormalities (ARIA), as well as immunogenicity and changes in amyloid and tau biomarkers in blood and brain. It will be conducted under Nuravax's investigational new drug application 30925.¹

How does the MultiTEP platform work?

AV-1959R is based on the MultiTEP platform, which combines self-antigen B-cell epitopes with foreign T-helper epitopes to generate antibodies against disease proteins, including Aβ, tau, and alpha-synuclein. IMM developed the platform and supplied the AV-1959R drug product, and Nuravax licenses the technology.¹

"Amyloid-beta builds up silently in the brain for up to two decades before symptoms appear, triggering the spread of tau that drives the disease," said Roman Kniazev, CEO of Nuravax, in the release.¹ "That silent window is precisely what a preventive vaccine is designed to address."

What are the limitations?

Fast track designation does not guarantee approval, and AV-1959R is not approved for any use. Its safety and efficacy have not yet been established.¹ The phase 1 trial was small and was not designed to assess clinical efficacy or to establish the safety profile needed for broader use.³ AREVIA is a planned study, and the company release did not disclose a start date, comparator arm, primary end point, or timeline for results. Whether vaccine-induced antibodies translate into reduced amyloid accumulation or delayed cognitive decline in a preclinical population remains to be demonstrated.

References

1. Nuravax. Nuravax receives FDA fast track designation for AV-1959R, an investigational vaccine designed to help prevent Alzheimer's disease before symptoms begin. Press release. Published October 20, 2026. Accessed October 20, 2026. https://prnmedia.prnewswire.com/news-releases/nuravax-receives-fda-fast-track-designation-for-av1959r-an-investigational-vaccine-designed-to-help-prevent-alzheimers-disease-before-symptoms-begin-302911695.html
2. FDA. Fast Track. Updated August 13, 2024. Accessed October 20, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
3. Nuravax. Nuravax and Institute for Molecular Medicine announce publication of phase 1 results for AV-1959R amyloid-beta vaccine. Press release. Published October 13, 2026. Accessed October 20, 2026. https://www.prnewswire.com/news-releases/nuravax-and-institute-for-molecular-medicine-announce-publication-of-phase-1-results-for-av-1959r-amyloid-beta-vaccine-302905613.html
4. AV-1959R vaccine in individuals with preclinical Alzheimer's disease (SAGITTARIUS). ClinicalTrials.gov; NCT07827768. Updated October 13, 2026. Accessed October 20, 2026. https://clinicaltrials.gov/study/NCT07827768